Cibus (CBUS) Other financing activities (2018 - 2021)

Cibus (CBUS) posted Other financing activities of $19000.0 for Q2 2021, down 90.87% sequentially from $208000.0 in Q1 2021.

Cibus (CBUS) Other financing activities (2018 - 2021) Analysis & Trends

Cibus has reported Other financing activities for 4 years, with the latest figure at $19000.0 in Q2 2021.

Quarterly Other financing activities changed N/A year-over-year to $19000.0 in Q2 2021, while the trailing twelve-month figure through Mar 2022 was $19000.0 (down 95.48% YoY) and the FY2021 annual result came in at $227000.0, up 7.08% from the prior year.
Other financing activities declined to $19000.0 in Q2 2021 per CBUS's latest filing, from $208000.0 in the prior quarter.
Over five years, Other financing activities peaked at $887000.0 in Q3 2018 and troughed at $1000.0 in Q4 2020.
A 4-year average of $283750.0 and a median of $195500.0 in 2019 frame the typical range for Other financing activities.
The sharpest annual moves came in 2019 and 2020: Other financing activities slumped 99.32% in 2019, then soared 3416.67% in 2020.
Over 4 years, Other financing activities stood at $494000.0 in 2018, then sank by 93.93% to $30000.0 in 2019, then slumped by 96.67% to $1000.0 in 2020, then surged by 1800.0% to $19000.0 in 2021.
According to Business Quant data, Other financing activities over the past three periods registered $19000.0, $208000.0, and $1000.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cibus	129.72 Mn	109.29 Mn	-

Download Data